289 related articles for article (PubMed ID: 32597089)
21. The Prognostic Role of Glutathione Peroxidase 1 and Immune Infiltrates in Glioma Investigated Using Public Datasets.
Lv S; Luo H; Huang K; Zhu X
Med Sci Monit; 2020 Oct; 26():e926440. PubMed ID: 33085656
[TBL] [Abstract][Full Text] [Related]
22. Correlation of AIF-1 Expression with Immune and Clinical Features in 1270 Glioma Samples.
Rao M; Yang Z; Huang K; Liu W; Chai Y
J Mol Neurosci; 2022 Feb; 72(2):420-432. PubMed ID: 34939148
[TBL] [Abstract][Full Text] [Related]
23. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
[TBL] [Abstract][Full Text] [Related]
24. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
[TBL] [Abstract][Full Text] [Related]
25. Expression and prognostic value of long non-coding RNA H19 in glioma via integrated bioinformatics analyses.
Xiao Y; Zhu Z; Li J; Yao J; Jiang H; Ran R; Li X; Li Z
Aging (Albany NY); 2020 Feb; 12(4):3407-3430. PubMed ID: 32081833
[TBL] [Abstract][Full Text] [Related]
26. ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy.
Cheng X; Liu Z; Liang W; Zhu Q; Wang C; Wang H; Zhang J; Li P; Gao Y
Int J Biochem Cell Biol; 2023 May; 158():106409. PubMed ID: 36997057
[TBL] [Abstract][Full Text] [Related]
27. Bioinformatics analysis of C3 in brain low-grade gliomas as potential therapeutic target and promoting immune cell infiltration.
Wu S; Miao K; Wang L; Ma Y; Wu X
Med Oncol; 2022 Jan; 39(2):27. PubMed ID: 35018510
[TBL] [Abstract][Full Text] [Related]
28. CNPY4 is a potential promising prognostic-related biomarker and correlated with immune infiltrates in gliomas.
Li JW; Huang QR; Mo LG
Medicine (Baltimore); 2022 Aug; 101(33):e30044. PubMed ID: 35984129
[TBL] [Abstract][Full Text] [Related]
29. S100A gene family: immune-related prognostic biomarkers and therapeutic targets for low-grade glioma.
Zhang Y; Yang X; Zhu XL; Bai H; Wang ZZ; Zhang JJ; Hao CY; Duan HB
Aging (Albany NY); 2021 Jun; 13(11):15459-15478. PubMed ID: 34148033
[TBL] [Abstract][Full Text] [Related]
30.
Chen Z; Cui S; Dai Y; Lu C; Zhang H; Zhao W; Yan H; Zhang Y
Oxid Med Cell Longev; 2022; 2022():7595230. PubMed ID: 36193074
[TBL] [Abstract][Full Text] [Related]
31. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
Liu J; Xu K; Ma L; Wang Y
Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
[TBL] [Abstract][Full Text] [Related]
32. Expression, Prognosis, and Immune Infiltrates Analyses of E2Fs in Human Brain and CNS Cancer.
Liao P; Han S; Qu H
Biomed Res Int; 2020; 2020():6281635. PubMed ID: 33381564
[TBL] [Abstract][Full Text] [Related]
33. PTPRN Serves as a Prognostic Biomarker and Correlated with Immune Infiltrates in Low Grade Glioma.
Li P; Chen F; Yao C; Zhu K; Zhang B; Zheng Z
Brain Sci; 2022 Jun; 12(6):. PubMed ID: 35741647
[TBL] [Abstract][Full Text] [Related]
34. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
[TBL] [Abstract][Full Text] [Related]
35. Elevated expression of mitochondrial transcription elongation factor (TEFM) predicts poor prognosis in low grade glioma-an analysis of the Cancer Genome Atlas (TCGA) dataset.
Li S; Wang W; Zi J; Sun M; Mei W; Yang N; Zhang R; Yu M; Xiong W
Transl Cancer Res; 2020 May; 9(5):3610-3622. PubMed ID: 35117724
[TBL] [Abstract][Full Text] [Related]
36. Co-amplified with PDGFRA, IGFBP7 is a prognostic biomarker correlated with the immune infiltrations of glioma.
Wang H; Wang X; Xu L; Zhang J
Cancer Med; 2023 Feb; 12(4):4951-4967. PubMed ID: 36043552
[TBL] [Abstract][Full Text] [Related]
37. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics.
Lin WW; Ou GY; Zhao WJ
J Cell Mol Med; 2021 Nov; 25(21):10111-10125. PubMed ID: 34597473
[TBL] [Abstract][Full Text] [Related]
38. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
39. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
Front Neurol; 2022; 13():977180. PubMed ID: 36353126
[TBL] [Abstract][Full Text] [Related]
40. Immune Infiltration-Related Signature Predicts Risk Stratification and Immunotherapy Efficacy in Grade II and III Gliomas.
Luo C; Liu Z; Ye W; Liu F
Front Cell Dev Biol; 2021; 9():756005. PubMed ID: 34805164
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
